Plasmid DNA (pDNA) is a fundamental starting material for therapeutic development, including for viral vectors, mRNA therapies, and DNA vaccines. Researchers use capture methods such as anion exchange ...

Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.

Plasmids, small circular DNA molecules found in bacteria, may contain antibiotic-resistance genes and have the ability to replicate independently. Bacteria can transfer these plasmids to one another, ...

Nucleic acid purification procedures have enjoyed a long history, beginning with the first isolation of "nuclein" in 1869 by Freidrich Meischer. In 1958, Matthew Meselson and Frank Stahl demonstrated ...

DNA-based information is a new field hoping to fill the gap in long-term data storage by using DNA as an information storage medium. Despite DNA’s potential, researchers face problems accurately ...

As cell and gene therapies, mRNA vaccines and other cutting-edge meds come into their own, developers have put a strain on the industry's supply chain. That’s where biopharma building block outfits ...

DNA vaccines, wherein a new antigen is inserted into a validated vector, have tremendous potential for deployment in pandemic applications as they can be rapidly produced in a validated, ...